Literature DB >> 9457196

Percutaneous abdominal biopsy: cost-identification analysis.

S G Silverman1, T E Deuson, N Kane, D F Adams, S E Seltzer, M D Phillips, R Khorasani, M J Zinner, B L Holman.   

Abstract

PURPOSE: To determine the difference in cost to providers of percutaneous abdominal biopsy as the first strategy versus surgical biopsy.
MATERIALS AND METHODS: Cost of tissue diagnosis determination with percutaneous biopsy as the first strategy in 439 patients with an abdominal mass was estimated. Costs included direct hospital costs and professional costs of initial and repeat biopsy, follow-up imaging and clinic visits, surgical biopsy (when needed), and treatment of complications. The sum of these costs was compared with the estimated cost had the same patients undergone surgical biopsy instead, with no complications or need for follow-up or repeat biopsy.
RESULTS: The total estimated cost of percutaneous biopsy as the first strategy ($543,245) was less than the cost had surgical biopsy been used alone ($1,919,867). The average per patient direct hospital cost of percutaneous biopsy ($800) was lower than that of surgical biopsy ($3,419). The average per patient professional cost of percutaneous biopsy ($438) was also lower than that of surgical biopsy ($955). Savings averaged $3,136 per patient, or $1,376,622 for the study period.
CONCLUSION: Substantial health care cost savings may result by using a diagnostic algorithm in which percutaneous biopsy is the first strategy for establishment of a diagnosis in patients suspected of having abdominal malignancy.

Entities:  

Mesh:

Year:  1998        PMID: 9457196     DOI: 10.1148/radiology.206.2.9457196

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Cost comparison analysis of low-field (0.23 T) MRI- and CT-guided bone biopsies.

Authors:  J Alanen; L Keski-Nisula; R Blanco-Sequeiros; O Tervonen
Journal:  Eur Radiol       Date:  2003-06-25       Impact factor: 5.315

2.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

Review 3.  Latest biopsy approach for suspected metastases in patients with breast cancer.

Authors:  Naoki Niikura; Bruno C Odisio; Yutaka Tokuda; Fraser W Symmans; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Nat Rev Clin Oncol       Date:  2013-10-22       Impact factor: 66.675

4.  Multidetector computed tomography-based microstructural analysis reveals reduced bone mineral content and trabecular bone changes in the lumbar spine after transarterial chemoembolization therapy for hepatocellular carcinoma.

Authors:  Miyuki Takasu; Takuji Yamagami; Yuko Nakamura; Daisuke Komoto; Yoko Kaichi; Chihiro Tani; Shuji Date; Masao Kiguchi; Kazuo Awai
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

5.  Image-Guided Cancer Nanomedicine.

Authors:  Dong-Hyun Kim
Journal:  J Imaging       Date:  2018-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.